Document is current

Article History

Received: 30 May 2025

Revised: 24 June 2025

Accepted: 25 June 2025

First Online: 31 October 2025

Declarations

:

: Drs. Dillman, Baker, Ream, Bruining, Rieder, Bartlett, Fidler, Denson, and Fletcher receive grant support from The Leona M. And Harry B. Helmsley Foundation, which provided partial support for this work via a grant to Drs. Dillman and Denson (co-PI’s, “Artificial Intelligence Prediction of Meaningful Outcomes in Newly Diagnosed Small Bowel Crohn’s Disease”). Drs. Dillman, Baker, Ream, Bruining, Rieder, Fidler, Denson, and Fletcher also receive other grants from The Leona M. And Harry B. Helmsley Foundation, including those to the Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. Mark E. Baker, M.D. receives funding to the institution from Pfizer and Merck.Florian Rieder, M.D. is consultant to or on advisory board of Adiso, Adnovate, Agomab, Allergan, AbbVie, Arena, Astra Zeneca, Bausch & Lomb, Boehringer-Ingelheim, Celgene/BMS, Celltrion, CDISC, Celsius, Cowen, 89Bio, Eugit, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Granite, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis Limited, Index Pharma, Landos, Jannsen, Koutif, Mestag, Metacrine, Mirum, Mobius, Mopac, Morphic, Myka Labs, Organovo, Origo, Palisade, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Sanofi, Surmodics, Surrozen, Takeda, Techlab, Teva, Theravance, Thetis, Tr1x Bio, UCB, Ysios DHB is a consultant to Johnson & Johnson.Jonathan R. Dillman, M.D., M.Sc. reports unrelated research support from Bracco, GE HealthCare, Guerbet, Motilent, Perspectum, and Philips Healthcare.Joel G. Fletcher is also the recipient of a research grant to the institution from Siemens Healthineers, unrelated to this work, as well as Alimentiv, Pfizer. He is co-investigator with motillent. JGF is a consultant with funds to institution from Genentech, Boehringer Ingelheim, Glaxo Smith Kline, Janssen, Medtronic, Takeda, Alimentiv, Inc. Red X Pharma.